Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- PAR-25-106
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $475,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- Independent School Districts
- Public or Indian Housing Auth.
- Non-501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- State Governments
- Small Businesses
- Higher Education Inst. (Public)
- County Governments
- City/Township Governments
- Tribal Organizations (Not Federally Recognized)
- 501(c)(3) Nonprofits
- For Profit Organizations
- Other
- Tribal Governments (Federally Recognized)
- Special District Governments
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute (NCI) is seeking applications for the Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) grant program. This funding opportunity encourages the use of nanotechnology to address major barriers in cancer biology and/or oncology, with a focus on mechanistic studies to understand nanomaterial and/or nanodevice interactions with biological systems. Proposed projects should aim to produce fundamental knowledge to aid future development of nanotechnology-based cancer interventions, though clinical translation is outside the scope of this Notice of Funding Opportunity (NOFO). Eligible applicant types include 501(c)(3) nonprofits, small businesses, and state/local governments. The NOFO is due on May 4, 2026.
Recent Federal Grant Awards under the associated Cancer Detection and Diagnosis Research (93.394) and Cancer Treatment Research (93.395) programs have ranged from approximately $200,000 to over $1.6 million in total costs, with typical project periods spanning 2-5 years. The majority of the research is expected to be conducted at the applicant organizations' facilities across the United States, with some international collaboration components possible for clinical trials networks.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize mechanistic studies toward fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. These studies should be performed in context of research concerning the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is outside of the scope of this NOFO.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-106-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity